EPA-0849 – Factors affecting compliance with therapy in psychiatric inpatients during treatment

Abstract

Introduction:Schizophrenia and psychotic disorders represent psychiatric disease patterns characterized by great impairment due to disease severity with a great effect in patient's health related quality of life, which still remain a challenge in everyday clinical practice.Aim:To investigate group differences in health related quality of life(HRQoL) in patients with psychosis during in hospital treatment.Methods:174 inpatients in a psychiatric ward in Athens-Greece participated in the study. 120(69%) were males and 54(31%) females. Of them, 0(11.5%) had bipolar disorder(BD), 126(72.4%) psychosis and depression(PD) and 28(16.1%) comorbit alcohol addiction(PAA). Patients filled a battery with tests of HrQoL, psychotic symptoms, negative motions, optimism, self-esteem, happiness and life-satisfaction. Stepwise regression models were used to determine the best predictors of compliance with SPSS.Results:There were a statistical significant difference in compliance between BD and PAA(good compliance 100%) and PD(good compliance 66.7%)(x2=21.09p=.001). Multivariate analysis revealed that good reaction to treatment(beta=−.736), atypical antipsychotics(beta=− .312), antidepressants(beta=−.270), days of hospitalization(beta=.203), bipolar disorder(beta=.199), sleeping pills(beta=.169) and stabilizers(beta=−.188) explained 74.5% of the variance in compliance(adjusted R2=.745 p<0.001). In a second model with the inclusion of personality and emotional characteristics in the model, stress(beta=−.381) negative emotions (DASS)(beta=.290) and subjective happiness(beta=.120) explained an additional 3% in compliance with therapy(adjusted R2=.775 p<0.001).Conclusions:It seems that depression comorbidity is an effective factor affecting therapy compliance in psychosis, with days staying in hospital for treatment. Also if the patient is prior to the therapy happy with his life complies better with the pharmacological approach that was used during the days of treatment.

Measuring the effectiveness of psychoeducation on adherence, depression, anxiety and stress among patients with diagnosis of schizophrenia. a control trial

“…To the best of our knowledge there are no studies on the relationship between anxiety, or stress and attitudes towards medication in mental disorders or schizophrenia research, while there are a few studies with reported outcome concerning the relationship between depression and adherence, with mixed results (Beck et al 2011;Kane et al 2013;Kleim et al 2008;Lyrakos et al 2014;Na et al 2015;Perkins et al 2006;Perkins et al 2008;Santone et al 2008;Sapra et al 2008;Steger et al 2012;Yang et al 2012). In addition, more research is needed for the exploration of the effect of psychoeducation on depression, distress and adherence in schizophrenia (Xia et al 2011).…”

“…In schizophrenia, depression and negative symptomatology are found to be both a significant (Kane et al 2013;Lyrakos et al 2014;Na et al 2015) and a non-significant predictor of patients' attitudes towards medication (Steger et al 2012;Yang et al 2012). Contrastingly, depression is always a predictor of reduced motivation and negative attitudes towards medication among patients in the general medical pathology regimens (DiMatteo et al 2000;Gonzalez et al 2008;Grenard et al 2011).…”